Exploring scalable, data-driven AAV manufacturing to achieve high yield and quality across serotypes

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Exploring scalable, data-driven AAV manufacturing to achieve high yield and quality across serotypes

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Attend this webinar to learn about real-world case studies using data-driven selection criteria for plasmid vectors, cell lines, and media, in order to optimize upstream processes and achieve higher yield and quality across different AAV serotypes.

Attendees will gain insights into optimizing the entire AAV process, including data on:

A transfection system that has demonstrated scalability and consistency, achieving over 7.0E16 GC AAV8 in a 50L SUB bioreactor, with a high yield of >1.6E15 VG/L for AAV8 production
Engineered pRep2/CapX packaging plasmids for improved yields and quality for both natural and synthetic serotypes
DOE-based transfection optimization to increase titer yields by up to 70-fold
Robust, scalable downstream processes that include clarification, TTF, affinity chromatography, and anion-exchange chromatography for full capsid enrichment
Approaches for scalable rAAV manufacturing strategies from benchtop (<10L) to pilot (50L) scale

Attend this webinar to:

Learn about an optimized AAV process development framework: leverage a structured DOE-based transfection optimization approach to enhance viral vector production efficiency and reproducibility
Understand the advantages of data-driven plasmid and serotype selection: data-driven selection criteria for plasmid vectors, cell lines, and media allows for optimization of upstream processes for higher yield and quality across different AAV serotypes
Stay ahead of trends: understanding the latest advancements in AAV platform development – including engineered packaging plasmids that improve yields and quality across various serotypes – is critical to remaining competitive in the evolving gene therapy landscape

Xiaojun Liu

Director at ReciBioPharm

Xiaojun Liu is a seasoned bioprocess leader with over 20 years of gene therapy experience, focusing on viral vector (AAV/LV) development and CMC strategy. As Director at ReciBioPharm, a Recipharm company, he leads AAV/LV process development cross—functional teams upstream, downstream, and analytically through IND-enabling studies and tech transfer to cGMP manufacturing. He’s helped advance multiple gene therapy programs in liver, ocular, and cardiovascular indications. Dr Liu has published 60+ papers with over 8,300 citations and brings a strong track record from previous roles at EdiGene Biotech USA and Luye Pharma. He trained at Harvard Medical School and is currently Associate Editor for Molecular Biotechnology and an incoming member of ASGCT’s Viral Gene Transfer Vectors Committee.

Chris Brown

Senior Scientist at ReciBioPharm

Chris Brown is a Process Development Senior Scientist at ReciBioPharm, the biologics division of the global CDMO Recipharm. Chris holds Bachelors (BSc) and Masters (MSc) degrees in Chemical Engineering from Northeastern University. He has greater than 8 years of experience across both process development and CMC, with six of those years dedicated specifically to the advancement of rAAV and LVV manufacturing. Chris has been with ReciBioPharm for two years, where he has focused on developing robust, scalable viral vector manufacturing processes and tailoring these processes to meet client needs.

Yeonji Kim

Scientist I at ReciBioPharm

Yeonji Kim is a Process Development Scientist I at ReciBioPharm, where she has been focused on developing robust downstream platforms for rAAV and LVV manufacturing and scale up. over the past two years. She earned her Bachelor’s degree in Biology from Muhlenberg College and is currently pursuing a Master’s in Regulatory Science at Johns Hopkins University. Yeonji brings a decade of research experience, including four years specializing in viral vectors. Her expertise spans upstream processing, downstream purification, and analytical development.

in 12

Days